Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxyresorufin SCHEMBL31079400 | 0.90 | APP (1.00) | APPCYP1A2CA12CA1CA4 | |
| Ethoxyresorufin SCHEMBL104497 | 0.90 | APP (1.00) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL1104925 | 0.88 | APP (0.80) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL1104928 | 0.87 | APP (0.69) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL16069679 | 0.85 | APP (0.81) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL22901183 | 0.85 | APP (0.83) | APPCYP1A2F2RL3 | |
| SCHEMBL1093700 | 0.84 | APP (0.67) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL505449 | 0.83 | APP (0.78) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL31492097 | 0.83 | APP (0.78) | APPCYP1A2CA12CA1CA4 | |
| SCHEMBL10167882 | 0.83 | APP (1.00) | APPCYP1A2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153828-B2 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153828-B2 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100105095-A1 | Optical Molecular Sensors for Cytochrome P450 Activity | Life Technologies Corporation (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105095-A1 | Optical Molecular Sensors for Cytochrome P450 Activity | Life Technologies Corporation (US) | 2010-04-29 | — | — | US | disclosed |
| US-20080125586-A1 | Optical molecular sensors for cytochrome P450 activity | INVITROGEN CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125586-A1 | Optical molecular sensors for cytochrome P450 activity | INVITROGEN CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20070072256-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | INVITROGEN CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072256-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | INVITROGEN CORPORATION | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105095-A1 | Optical Molecular Sensors for Cytochrome P450 Activity | CYP2J2, CYP1A2, CYP2B6 | APP 3233/4885CYP1A2 2/4885CA12 2350/4885 |
| US-20080125586-A1 | Optical molecular sensors for cytochrome P450 activity | CYP2J2, CYP1A2, CYP2B6 | APP 3233/4885CYP1A2 2/4885CA12 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.